ZBIO FY 2023 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena

ZBIOZenas BioPharma, Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M

Gross Profit

$50M100.0% margin

Operating Income

-$37M-74.3% margin

Net Income

-$37M-74.2% margin

EPS (Diluted)

$-0.97

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$68M

Total Liabilities

$294M

Stockholders' Equity

-$226M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$0	—
Gross Profit	$50M	-$62M	+181.1%
Operating Income	-$37M	-$76M	+51.3%
Net Income	-$37M	-$119M	+68.9%